Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: February 3, 2023

Details for Patent: 6,534,524

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 6,534,524 protect, and when does it expire?

Patent 6,534,524 protects INLYTA and is included in one NDA.

This patent has eighty-two patent family members in fifty-one countries.

Summary for Patent: 6,534,524
Title: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Abstract:Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Inventor(s): Kania; Robert Steven (San Diego, CA), Bender; Steven Lee (Oceanside, CA), Borchardt; Allen J. (San Diego, CA), Cripps; Stephan James (San Diego, CA), Hua; Ye (La Jolla, CA), Johnson; Michael David (San Diego, CA), Johnson, Jr.; Theodore Otto (San Diego, CA), Luu; Hiep The (San Diego, CA), Palmer; Cynthia Louise (San Diego, CA), Reich; Siegfried Heinz (Solana Beach, CA), Tempczyk-Russell; Anna Marie (Ramona, CA), Teng; Min (San Diego, CA), Thomas; Christine (West Borough, MA), Varney; Michael David (Solana Beach, CA), Wallace; Michael Brennan (San Diego, CA), Collins; Michael Raymond (San Diego, CA)
Assignee: Agouron Pharmaceuticals, Inc. (La Jolla, CA)
Application Number:09/983,783
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,534,524

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,534,524

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1486 See Plans and Pricing
Argentina 035554 See Plans and Pricing
Argentina 065937 See Plans and Pricing
Austria 376543 See Plans and Pricing
Australia 5785200 See Plans and Pricing
Australia 777701 See Plans and Pricing
Bulgaria 106380 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.